HORSHAM, PA, USA—AUGUST 23, 2011—DIA will bring together biopharmaceutical and medical device experts as well key agency personnel from NLM, FDA and EMA at The Evolving Clinical Trials Disclosure Landscape Conference, which will be held September 13-14 in Arlington, VA.
This two-day conference will explore ways to ensure compliance, efficiency, and consistency in clinical trial disclosure. This year’s conference will offer collaborative breakout sessions that will give attendees an opportunity to interact with and gain practical advice from colleagues, peers, and other stakeholders. Topics will include:
- US, Regional, and International Clinical Trial Registries
- Leveraging Information Technology to Upload to Registries and Results Databases
- Registries, Results Databases, and the Interrelationships with Publications
- Devices and Disclosure
- Impact of Disclosure on NIH Research/Academia
- FDA Plans for Auditing Procedures
- Collaborative Breakout Session Topics:
- Preparing your protocol and CSR for future disclosure
- Post-market and observational studies
- ClinicalTrials.gov quality review
- Challenges unique to small companies and academic researchers
Register for The Evolving Clinical Trials Disclosure Landscape Conference.
ABOUT DIA
DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India and Beijing, China.
